PAX5 and neoplasm: CHL tumor cells were positive for PAX5 (10/12, 83.3%), CD30 (12/12, 100%), CD15 (9/12, 75.0%), CD20 (4/12, 33.3%) and CD79a (2/9, 22.2%).